share_log

Brookline Capital Initiates Coverage On Forte Biosciences With Buy Rating, Announces Price Target of $4

Benzinga ·  May 30 17:56

Brookline Capital analyst Kumaraguru Raja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price Target of $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment